Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
ResMed (RMD) Delivers Steady Q1 Growth and Reaffirms Outlook

ResMed (RMD) Delivers Steady Q1 Growth and Reaffirms Outlook

Key Takeaways

  • ResMed reported revenue of approximately $1.415 billion for the first quarter of fiscal 2027, up 6% year over year and 7% on a core constant currency basis, topping consensus estimates near $1.39 billion.
  • GAAP diluted EPS rose 23% to $2.92, while non-GAAP diluted EPS increased 14% to $2.91, both above analyst expectations.
  • Non-GAAP gross margin expanded 50 basis points to 62.5%, driven by strong demand across sleep devices and masks and accessories.
  • The company returned more than $1.0 billion to shareholders through share repurchases and dividends and closed the divestiture of its MatrixCare business.
  • Full-year fiscal 2027 guidance was reaffirmed, including core constant currency revenue growth of 5% to 7% and non-GAAP diluted EPS of $12.00 to $12.25.
  • For more detail on ResMed's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for the ticker.
  • Explore Trending AI Robots to discover AI-driven trading strategies and market insights.

Why These Results Matter

ResMed's first-quarter results mark the start of fiscal 2027 and highlight a business that has delivered consistent mid-to-high single-digit growth in its core sleep and breathing health segment. With a large installed base of cloud-connected devices and recurring revenue from masks and accessories, the quarter provides insight into patient demand, pricing trends, and market share dynamics. The report is especially relevant after the divestiture of the MatrixCare software business, which sharpens focus on the respiratory franchise and frees up capital for innovation and returns to shareholders. I think these figures help gauge whether steady demand can continue to offset currency pressures and competition.

Breaking Down the Reported Numbers

ResMed reported net revenue of approximately $1.415 billion for the first quarter of fiscal 2027, ended September 30, 2026, representing a 6% increase from the prior-year period. On a core constant currency basis that adjusts for currency moves and excludes the Noctrix acquisition and MatrixCare divestiture, revenue grew 7%. The result surpassed the roughly $1.39 billion consensus estimate. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

On the bottom line, GAAP diluted EPS rose 23% to $2.92, while non-GAAP diluted EPS climbed 14% to $2.91, both exceeding analyst forecasts. GAAP gross margin stood at 61.5%, and non-GAAP gross margin widened 50 basis points to 62.5%. Operating cash flow reached $422 million, with free cash flow at $374 million.

Management reaffirmed its full-year fiscal 2027 outlook of 5% to 7% core constant currency revenue growth, reported revenue between $5.75 billion and $5.85 billion, and non-GAAP diluted EPS of $12.00 to $12.25. The board also approved a quarterly cash dividend of $0.66 per share.

Market Reaction and Sentiment

ResMed shares moved modestly higher after the report, reflecting a quarter that exceeded both revenue and earnings expectations while maintaining full-year guidance. The combination of top-line strength, gross margin improvement, and a steady outlook was viewed positively, though the measured response suggests much of the performance had already been priced in. From what I see, investor sentiment remains supported by reliable demand for sleep and breathing health products along with a consistent capital-return program. Background risks include foreign exchange headwinds, competition in the sleep device space, and the rollout of new products such as the AirTouch F40 fabric mask.

Looking Ahead: Factors to Watch

Going forward, attention will center on whether ResMed can maintain core constant currency growth within the 5% to 7% range for fiscal 2027. Management continues to highlight expansion of its digital health ecosystem and greater patient connectivity to home-based care, points emphasized during the earnings call.

Margin trends also warrant monitoring. The 50-basis-point gain in non-GAAP gross margin stemmed from productivity improvements, and sustained progress here will matter as the company integrates recent product launches and manages supply-chain and cost factors.

Capital allocation is another key element. After returning more than $1.0 billion to shareholders in the quarter, partly funded by MatrixCare proceeds, ResMed is balancing reinvestment in innovation with cash returns. Near-term catalysts include traction for new mask products, adoption of software and digital health solutions, and any updates on competitive or regulatory developments in global markets.

How Tickeron’s AI Screener Supports My Research

In my day-to-day analysis, Tickeron’s AI Screener serves as a practical tool for scanning the market and spotting relevant signals. It allows filtering by technical patterns, fundamentals, and performance metrics, helping surface ideas across sectors without manual effort. For names like ResMed, it provides a structured way to compare opportunities and stay informed on evolving conditions. Learn more about Tickeron’s AI Screener.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RMD

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


RMD's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for RMD moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 instances where the indicator moved out of the overbought zone. In 26 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a move down at 72%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 55 cases where RMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.

The Moving Average Convergence Divergence Histogram (MACD) for RMD turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 18 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 47%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.

RMD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on RMD as a result. In 60 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

RMD moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +0.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where RMD advanced for three days, in 188 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

The Aroon Indicator entered an Uptrend today. In 129 of 218 cases where RMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 40 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. RMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.154) is normal, around the industry mean (4.964). P/E Ratio (22.474) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (4.143). Dividend Yield (0.011) settles around the average of (0.006) among similar stocks. P/S Ratio (5.896) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of devices for evaluation and treatment of sleep disorders

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
9001 Spectrum Center Boulevard
Phone
+1 858 836-5000
Employees
11370
Web
https://www.resmed.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.